Journals / Turkish Journal of Zoology / 2020 / Cilt: 44 - Sayı: 2

Nonpharmacological treatment options for Alzheimer’s disease: from animal testing to clinical studies

Pages
81–89
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Nonpharmacological studies of AD are discussed in this literature review interms of animal models, physical activity, brain stimulation, and the role of social communication.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Despite extensive pharmacological approaches, there is no curative therapy for Alzheimer’s disease (AD) or other types ofdementias.
📊
Key Findings & Data:While current pharmacological options alleviate some symptoms of AD, they can lead to various adverse effects.
💡
Conclusion & Impact:Nonpharmacological studies of AD are discussed in this literature review interms of animal models, physical activity, brain stimulation, and the role of social communication.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Despite extensive pharmacological approaches, there is no curative therapy for Alzheimer’s disease (AD) or other types ofdementias. While current pharmacological options alleviate some symptoms of AD, they can lead to various adverse effects. Hence,nonpharmacological treatment options for AD are often considered with the assumption that they are safe, effective, and economic inmanaging patients. Furthermore, studies on animal models have suggested that environmental exposures like diet, music, or rewardrelatedactions can stimulate neuronal regeneration and differentiation without using any pharmacological factors. The aim of thisreview is to provide a summary of nonpharmacological treatment options for the management of cognitive, emotional, and behavioralsymptoms of AD. In addition, this review provides an overview of the challenging and encouraging experiences and recent studies andproblems in cognitive training related to animal models. Nonpharmacological studies of AD are discussed in this literature review interms of animal models, physical activity, brain stimulation, and the role of social communication.

🔖

Cite This Article

STEFANO, A. D., CACCIATORE, I., MARDİNOĞLU, A., ARSLAN, M. E., TÜRKEZ, H. (2022). Nonpharmacological treatment options for Alzheimer’s disease: from animal testing to clinical studies. Turkish Journal of Zoology, Cilt: 44 - Sayı: 2, 81–89. https://ajindex.com/articles/615966

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. Albarracin, SL, Stab B, Casas Z, Sutachan JJ, Samudio I et al. (2012). Effects of natural antioxidants in neurodegenerative disease. Nutritional Neuroscience 15 (1): 1-9. doi: 10.1179/1476830511Y.0000000028 Ambrée O, Leimer U, Herring A, Görtz N, Sachser N et al. (2006). Reduction of amyloid angiopathy and Aβ plaque burden after enriched housing in TgCRND8 mice. American Journal of Pathology 169 (2): 544-552. doi: 10.2353/ajpath.2006.051107 Annweiler C (2014). Vitamine D et maladie d’Alzheimer: d’une curieuse idée à une possibilité de traitement. Biologie Aujourd’hui 208 (1): 89-95 (in French). doi: 10.1051/ jbio/2014005 Azad N, Rasoolijazi H, Joghataie MT, Soleimani S (2011). Neuroprotective effects of carnosic acid in an experimental model of Alzheimer’s disease in rats. Cell Journal 13 (1): 39-44.
  2. Baumgart M, Snyder HM, Carrillo MC, Fazio S, Kim H et al. (2015). Summary of the evidence on modifiable risk factors for cognitive decline and dementia: a population-based perspective. Alzheimer’s and Dementia 11 (6): 718-726. doi: 10.1016/j.jalz.2015.05.016 Beauquis J, Pavía P, Pomilio C, Vinuesa A, Podlutskaya N et al. (2013). Environmental enrichment prevents astroglial pathological changes in the hippocampus of APP transgenic mice, model of Alzheimer’s disease. Experimental Neurology 239: 28-37. doi: 10.1016/j.expneurol.2012.09.009 Braidy N, Behzad S, Habtemariam S, Ahmed T, Daglia M et al. (2017a). Neuroprotective effects of citrus fruit-derived flavonoids, nobiletin and tangeretin in Alzheimer’s and Parkinson’s disease. CNS & Neurological Disorders - Drug Targets 16 (4): 387-397. doi: 10.2174/18715273166661703281 13309 Braidy N, Jugder BE, Poljak A, Jayasena T, Mansour H et al. (2016). Resveratrol as a potential therapeutic candidate for the treatment and management of Alzheimer’s disease. Current Topics in Medicinal Chemistry 16 (17): 1951-1960. doi: 10.217 4/1568026616666160204121431 Braidy N, Jugder BE, Poljak A, Jayasena T, Nabavi SM et al. (2017b). Molecular targets of tannic acid in Alzheimer’s disease. Current Alzheimer Research 14 (8): 861-869. doi: 10.2174/1567205014 666170206163158 Cacciatore I, Marinelli L, Fornasari E (2016). Novel NSAID-derived drugs for the potential treatment of Alzheimer’s disease. International Journal of Molecular Sciences 17: 1035. doi: 10.3390/ijms17071035 Cass SP (2017). Alzheimer’s disease and exercise. Current Sports Medicine Reports 16 (1): 19-22. doi: 10.1249/ JSR.0000000000000332 Chakraborty S, Bandyopadhyay J,